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Background: We retrospectively reviewed our series of 76 patients who underwent esophagectomy, with curative
intent, for esophageal carcinoma over the last 10 years.
Method: The mean age was 60 years ranging between 46 to 76 years. Fifty-seven patients had a squamous cell
carcinoma and 19 patients had an adenocarcinoma. In 15 cases induction therapy was accomplished prior to
surgery. A narrow gastric tube was used to restore continuity in 74 patients (97.3%). Medical records were reviewed
and data analysis was performed.
Results: Peri-operative mortality was 2.6%. Overall survival at 1, 3 and 5 years was 85,5%, 67,7% and 52,7%,
respectively, with no significant difference between the squamous cell disease group and the adenocarcinoma
group. Although T factor and stage at the time of surgery influenced overall survival, the presence of nodal
metastasis had the major impact on survival as confirmed by univariate and multivariate analysis with a 5 year
survival rate of 32% regardless of the use or not of adjuvant chemo-radiotherapy and the pathologic stage.
Conclusions: Esophagectomy still represents a valid treatment for esophageal carcinoma in well selected patients.
Both pT stage and N stage appear to be the most important factors determining survival for patients with
completely resected esophageal carcinoma.Background
Cancer of the esophagus, despite the advances in its
diagnosis and treatment, remains a highly lethal malig-
nancy that increased dramatically in incidence during the
last 3 decades [1]. Surgery is an effective modality treat-
ment, either alone or as a part of a multimodality ap-
proach, to obtain a local tumor control and the potential
for a long term survival. Reduction of complication and
mortality rate after esophagectomy are firmly connected
to an appropriate patient selection, meticulous execution
of a well-chosen surgical technique, and esophageal surgi-
cal experience, which bears a direct relationship to the
outcome. However, there are still several controversies* Correspondence: tiziano.degiacomo@tin.it
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distribution, and reproduction in any mediumin the optimal management of patients with resectable
esophageal carcinoma in surgical approach, extent of re-
section and lymphadenectomy, type of reconstruction
and site of the anastomosis. The objective of this study is
to review and report our experience performing curative
esophagectomy for esophageal carcinoma evaluating the
oncologic and functional outcome.
Methods
We retrospectively reviewed all the esophageal proce-
dures performed with curative intent (n=76) for esopha-
geal carcinoma at the Department of Thoracic Surgery
of the University of Rome “Sapienza” between January
1998 and July 2010. There were 50 male and 26 female
patients, ranging in age from 46 to 76 years (median age,
60 years). The most common presentation symptom was
mild or severe dysphagia.
Pre-operative diagnostic evaluation in all patients was
mainly based on endoscopic examination of the esophagusntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Characteristics and results in patients Cohort
(n=76)
Overall SCC (n=57) ADC (n=19) P value
Age (years) 60 [46 – 76] 61 [46–76] 57 [46–71] 0,09
Sex 0,78
Male 50 (65,79%) 37 (64,91%) 13 (68,42%)
Female 26 (34,21%) 20 (35,09%) 6 (31,58%)
Esophagectomy 0,76
Thoracotomy 64 (84,21%) 49 (85,96%) 15 (78,95%)
VATS 9 (11,84%) 6 (10,53%) 3 (15,79%)
Transhiatal 3 (3,95%) 2 (3,51%) 1 (5,26%)
pT factor <0,01
T1 10 (13,16%) 5 (8,77%) 5 (26,32%)
T2 33 (43.42%) 21 (36,84%) 12 (63,16%)
T3 33 (43,42%) 31 (54,39%) 0
pN factor 0,02
N0 35 (46,05%) 22 (38,60%) 13 (68,42%)
N+ 41 (53,95%) 35 (61,4%) 6 (31,58%)
Stage 0,01
I 9 (11,84%) 5 (8,77%) 4 (21,05%)
IIA 26 (34,21%) 17 (29,82%) 9 (47,37%)
IIB 15 (19,74%) 10 (17,54%) 5 (26,32%)
III 26 (34,21%) 25 (43,86%) 1 (5,26%)
Induction therapy 0,03
Yes 15 (19,74%) 8 (14,04%) 7 (36,84%)
No 61 (80,26%) 49 (85,96%) 12 (63,16%)
Complications 0,56
Pleural effusion 3 (3,94%) 2 (3,51%) 1 (5,26%)
Vocal cord paresis 2 (2,63%) 2 (3,51%) 0
Bronchial secretions 4 (5,26%) 3 (5,26%) 1 (5,26%)
Wound dehiscence 2 (2,63%) 1 (1,75%) 1 (5,26%)
Anastomotic stenosis 3 (3,94%) 1 (1,75%) 2 (10,53%)
SCC: Squamous Cell Carcinoma; ADC: AdenoCarcinoma;
VATS: Video-Assisted ThoracoScopy.
Continuous data are presented as median [range], categorical data as
numbers (percentages).
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patients (75%) had a squamous cell carcinoma (SCC) of
the mid esophagus and 19 (25%) had an adenocarcinoma
(ADC) of the distal esophagus. Whole body computed
tomography scan was performed to complete clinical sta-
ging, while presence of endobronchial tumor infiltration
was excluded in all cases by fiberoptic bronchoscopy.
Barium swallow, blood chemistry analysis, liver function
and cardio-respiratory evaluation completed the preopera-
tive assessment. Enteral or parenteral nutritional supple-
mentation was provided to patients with poor nutritional
status. Bowel preparation was undertaken in all patient
prior to surgery. A thoracic epidural catheter was placed
for post-operative analgesia.
Platinum based induction therapy regimen was accom-
plished in 15 patients preoperatively staged as IIB and
III disease. The protocol used consisted of three cycles
of 5-fluorouracil and cisplatin followed by CT scan re-
staging and endoscopy. In 12 patients we observed sig-
nificant clinical and radiologic down-staging while in the
remaining 3 the disease remained stable. All patients
underwent surgery 3 to 4 weeks after the end of neo-
adjuvant treatment.
All operations were performed with curative intent
and accomplished via right fifth intercostal space thoracot-
omy in the majority of the cases; right video-assisted
thoracoscopy was employed in selected case of early-stage
esophageal cancer and in patients with high cardio-
respiratory risk. Trans-hiatal esophagectomy was also re-
served in highly selected patients with stage I or IIA disease.
Continuity of alimentary tract was re-established by inter-
position of a “narrow” gastric tube or a part of colon when
the use of stomach was not feasible, prepared and mobi-
lized through a median laparotomy. The conduit was then
placed in the posterior mediastinum in the prevertebral
space (esophageal bed) and was pulled up to the neck. Left-
side cervicotomy and end-to-end complete mechanical
anastomosis was always performed using the technique
already described in the past [2]. Pyloroplasty was not con-
sidered necessary. Two-field radical lymphnode dissection
was routinely carried out in all cases.
Data analysis was performed with Statistica 7.0 (StatSoft
Inc, Tulsa, OK, USA). Continuous variables are expressed
as mean (± standard error) or as median [range]. Student
t-test and Mann–Whitney U-test were used to compare
for parametric and non-parametric variables, respectively.
Categorical data are expressed as frequencies (percent-
ages) and compared with the chi square test or Fisher
exact test. Survival was estimated using the Kaplan-Meier
method and comparisons between groups were made with
log-rank test. Univariate and multivariate analyses were
performed using Cox proportional hazards regression
model to look for independent predictors of survival.
Statistical significance was assessed at the 5% level.Results
Demographics of the patients and histologic diagnosis
are presented in Table 1.
Complete esophagectomy was performed in all patients:
in 64 cases through a right thoracotomy, in 9 using right
video-thoracoscopy, while in 3 patients (two cases of stage
I and one case of stage IIA disease), at the beginning of
our experience, a trans-hiatal esophagectomy was accom-
plished. Restoration of the alimentary tube was done in 74
cases using a narrow gastric tube; in 2 patients in whom
the stomach was not considered adequate because of previ-
ous partial gastrectomy we used colon as esophageal sub-
stitute. Median length of post-operative stay was 14 days
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tions were as follow: pleural effusion in 3 patients, tempo-
rary dysfunction of the left vocal cord in 2, retention of
secretions requiring fiber-bronchoscopy in 4 and thoracic
wound dehiscence in 2. The cervical anastomosis was
checked for leakage by roentgenograms with water-soluble
contrast medium usually 5 days after surgery. Three late
stenoses of the cervical anastomosis were successfully
treated with endoscopic dilation. One patient developed
local recurrence after two years involving the gastric tube.
Eighteen patients developed distant metastases.
The overall 30-days mortality rate was of 2.6% due to
2 cases of acute mediastinitis and necrosis of the graft
observed at the beginning of our experience.
Preoperative histological diagnosis was confirmed in
all cases: 57 patients had squamous cell carcinoma and
19 had adenocarcinoma.
Pathologic T factor staging was as follow: 10 patients
were staged as pT1, 33 as pT2 and the remaining 33 pa-
tients as pT3. A statistical significant difference was seen
in pT between histopathologic types since 94% of the pa-
tients with pT3 disease had a squamous cell carcinoma
(p<0.01). Forty-one patients had lymph nodes involvement
at histology (pN) with a clear prevalence in the group of
squamous cell carcinoma (SCC=35 versus ADC=6; p=0.02).
The median number of lymphnodes harvested was 22 and
41 patients (53%) with involvement were treated with
adjuvant chemotherapy. Radiation therapy was associated
in 33 patients with T3 disease.
The median survival of the cohort was of 69 months.
Overall survival was 85.5%, 67.7% and 52.7% at 1, 3 and
5 years, respectively (Figure 1). No difference in survival
was found between histologic types (Figure 2).
Patients over 65 years old tended to have a worst sur-























Figure 1 Overall survival of all patients after resection was 85.5%, 67difference did not reach statistical significance (p=0.06).
Survival was better in patients with stage I or IIA tumor
(p<0.01) independently of the histologic type. Patients
that did not receive neoadiuvant treatment tended to
have a better overall survival but this survival advantage
reached statistical significance only in patients with stage
IIB disease; p=0.05.
Univariate statistical analysis showed that pT1 or pT2
tumor and absence of lymph node involvement were posi-
tive predictive factors for survival after esophagectomy.
The type of histology and the use of induction chemo-
therapy apparently did not influence survival. Not surpris-
ingly, early stage disease (stage I or IIA) was a strong
positive predictive factor for long term survival. However,
on multivariate analysis, significance was found only for
pT stage, N involvement, and neoadiuvant treatment while
the absence of lymph node metastasis resulted as the most
important predictive factor for survival (Table 2).
Discussion
This is a retrospective study conducted in a single center
describing our experience in potentially curative esoph-
agectomy and esophageal reconstruction for cancer over
the last 10 years. Only few randomized trials have been
published on this topic probably for several reasons: sig-
nificant differences in esophageal cancer population, diffi-
culty in standardization of the surgical technique, limited
number of cases, few centers performing esophageal sur-
gery. First of all the choice of the surgical approach is
still debating.
Two major surgical strategies can be employed: en-
block trans-thoracic resection or an extended resection
with two or three field lymphoadenectomy. In alternative,
in order to reduce the incidence of perioperative morbidity
and mortality a trans-hiatal approach can be used. Several0 72 84 96 108 120
ince surgery
.7% and 52.7% at 1, 3 and 5 years, respectively.
































SCC 57 49 45 36 29 18 10 9 4 3 1
ADC 19 16 15 10 7 5 3 3 1 0 0
Figure 2 Overall survival of patients with esophageal carcinoma after resection subdivided into cell types of squamous cell carcinoma
(SCC) versus Adenocarcinoma (ADC).
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complication, wound dehiscence, chylous leakage, and in-
fection are higher after trans-thoracic esophagectomy
[2-4] than trans-hiatal approach. Also the intensive care
unit and the hospital length of stay are significantly longer
after trans-thoracic approach.
On the other hand, [5,6] trans-thoracic esophagectomy
seems associated with a significant trend toward im-
proved long term survival. We agree with this evidence
and in our series most of the patients underwent trans-Table 2 Cox regression analysis: predictors of overall
survival in patients Cohort (n=76)
Univariate
HR 95% CI P value
T factor (T1) 2,859 1,561 - 5,234 <0,01
N factor (N0) 8,606 3,262 - 22,703 <0,01
Stage (I) 2,503 1,688 - 3,713 <0,01
Stage (I/IIA) 8,983 3,423 - 23,373 <0,01
Histology (SCC) 0,699 0,29 - 1,684 0,427
Neoadiuvant (No) 1,78 0,831 - 3,815 0,139
Multivariate
T factor (T1) 8,211 2,351 - 28,671 <0,01
N factor (N0) 39,076 2,605 - 586,209 <0,01
Stage (I) 0,277 0,059 - 1,302 0,104
Histology (SCC) 1,654 0,557 - 4,912 0,364
Neoadiuvant (No) 4,704 1,684 - 13,137 <0,01
HR: Hazard Ratio; CI: Confidence Interval.thoracic esophagectomy. We performed a trans-hiatal
esophagectomy only in 3 cases due to the junctional
location of the tumor.
Although minimally invasive techniques are gaining in
popularity, until now large randomized trials are not
yet available. We performed video-assisted thoracoscopic
esophagectomy only in case of early stage cancer in patients
with high cardio-respiratory risk, in order to reduce the
post-operative morbidity. The stomach was the method of
reconstruction employed in most of the patients. We pre-
ferred to prepare a narrow gastric tube without performing
piloroplasty placed in the anatomical pre-vertebral position.
The advantages a narrow gastric tube are that it can be
pulled up easily to the neck without tension, its excellent
elasticity and reduced mediastinal encumbrance. Extra-
anatomical reconstructions (retro-sternal or subcutaneous)
might offer the theoretical advantage that a recurrent
tumor mass will not involve the new esophagus but this
choice requires a longer tube preparation. The extent of
lymphnode dissection required for patients with esophageal
cancer is still controversial. There are surgeons that prefer
three-field lymphadenectomy, which includes abdomen,
chest and neck, and proponents of the two-field lymphade-
nectomy, which includes abdomen and chest only. One of
the potential advantages of transthoracic approach is better
exposure and improved mediastinal lymphnode dissection
when compared to the trans-hiatal esophagectomy. On the
other hand, we preferred a two-field lymphadenectomy and
notwithstanding a cervical anastomosis was performed in
all cases. Although a multi-institutional trial reported that

























pT1-2 43 41 38 31 24 17 12 11 5 3 1






Figure 3 Overall survival of patients with esophageal carcinoma after resection subdivided into pT1/T2 versus pT3 tumor stage.
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tomy with cervical lymphnode metastaases 20% occurred in
patients with lower esophageal cancer, survival data are
conflicting; in addiction the alleged benefit of the three-field
lymphadenectomy has not been confirmed in a prospective
randomized trial. Furthermore, the associated morbidity is
higher ranging between 35% to 45% [7]. Another controver-
























N0 35 34 32 25 21
N+ 41 31 28 21 15
Figure 4 Overall survival of patients with esophageal carcinoma afterchest. Although proponents of intra-thoracic anastomosis
point out the reduced tension and a lower risk of anasto-
motic complication, we prefer to use cervical anastomosis
since it allows larger proximal margin of resection and in
case of leakage less risks of dangerous mediastinal infection.
The technique of our cervical anastomosis has been already
described [8]. We prefer to accomplish a complete mechan-
ical anastomosis. In our series we did not record any60 72 84 96 108 120
hs since surgery
Log-rank test p<0.01
17 11 10 5 3 1






resection subdivided into pN0 versus pN1 nodal stage.
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tion. Some authors reported a higher incidence of anasto-
motic strictures after stapled anastomosis in patients with a
small diameter of the esophagus [9]. In our series, only 3
patients (4,2%) developed a late stenosis successfully
treated with endoscopic dilation. Because gastric emptying
may be impaired after esophagectomy and esophageal re-
construction with stomach, the use of pyloroplasty may be
employed. A meta-analysis by Urschel et al. [10] showed
that routine pyloroplasty is unnecessary. We agree with
them and in our series we never performed pyloroplasty
and we did not observe impaired gastric emptying.
Furthermore, pyloroplasty might increase the risk of
duodeno-gastric biliary reflux for gastric tube placed in the
anatomical pre-vertebral position [11].
At our institution, platinum based induction chemother-
apy is preferred to chemo-radiotherapy in locally advanced
tumors with the potential benefits of earlier treatment of
micro-metastases and down-staging of tumor. Although
randomized studies did not have shown a consistent bene-
fit in term of survival [12-14] in our series 12 patients (%)
presented down-staging of tumor and in 3 no residual
tumor was histologically found. In this group, median
survival was 38 months and 5 year survival was 44,8%.
Comparison of survival between patients undergone in-
duction chemotherapy and surgery versus surgery alone
was not statistically different suggesting the efficacy of in-
duction chemotherapy in terms of down-staging of tumor
and survival. Moreover, although in the literature several
studies reported an increased risk of surgical complica-
tions after induction chemotherapy [12,13], this observa-
tion was not confirmed in our series. Early pathologic
tumor stage (pT) with less degree of trans-mural invasion
carried a significant survival advantage (Figure 3). prob-
ably also because the prevalence of nodal metasteses
increase with increasing depth of tumor penetration into
the esophageal wall [15]. In our study, we have found that
N0 patients had significant improvement in long term
survival. (Figure 4) with a 5-year survival of 87,7%.
Conclusions
Surgical resection is currently the treatment of choice for
patients with resectable esophageal carcinoma. Although
there are still several controversies regarding the optimal
management of these patients, based on more than 10
year experience, our current and preferred approach is to
perform a trans-thoracic esophagectomy with two-field
lymphoadenctomy and cervical mechanical anastomosis.
The advantages of this approach are the potential for an
improved rate of complete resection, mediastinal lymph-
adenectomy and lower rate of anastomotic complications
with a good functional outcome. In our series both T and
N status appear to be the most important factors deter-
mining long term survival. Controversial issues in thisfield require further prospective studies to evaluate the dif-
ferent approaches to esophageal carcinoma.
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